Functional gene variation in the human norepinephrine transporter - Association with attention deficit hyperactivity disorder

被引:28
作者
Kim, Chun-Hyung [1 ]
Waldman, Irwin D. [2 ]
Blakely, Randy D. [3 ,4 ]
Kim, Kwang-Soo [1 ]
机构
[1] Harvard Univ, McLean Hosp, Sch Med, Mol Neurobiol Lab, Belmont, MA 02478 USA
[2] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA
[3] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA
来源
MOLECULAR AND BIOPHYSICAL MECHANISMS OF AROUSAL, ALERTNESS, AND ATTENTION | 2008年 / 1129卷
关键词
norepinephrine transporter; promoter; polymorphism; snail family; ADHD;
D O I
10.1196/annals.1417.023
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The norepinephrine (NE) transporter (NET) is responsible for the re-uptake of NE into presynaptic nerve terminals, thus critically regulating noradrenergic signaling and homeostasis. Since NE signaling contributes to diverse brain functions, we hypothesize that promoter variation within the human NET gene (solute carrier family 6, member 2; SLC6A2) may impact risk for NE-related disorders, including depression, attention deficit hyperactive disorder (ADHD), and autonomic dysfunction. In support of this, we recently found a functional polymorphism at -3081 position upstream of the transcription initiation site. This polymorphism displayed differential promoter function, which we showed could arise from recruitment of a transcriptional repressor. Further analyses identified Slug and Scratch as candidates involved in repression of SLC6A2 transcription generated by the -3081(T) allele. Moreover, we observed a significant association of the -3081(T) variant with ADHD. Altered transcription of SLC6A2 may therefore represent a novel risk factor for the development of ADHD.
引用
收藏
页码:256 / 260
页数:5
相关论文
共 43 条
[1]  
Anand A, 2000, J CLIN PSYCHIAT, V61, P16
[2]   NORADRENALINE - FATE AND CONTROL OF ITS BIOSYNTHESIS [J].
AXELROD, J .
SCIENCE, 1971, 173 (3997) :598-+
[3]  
Barkley RA, 1997, J DEV BEHAV PEDIATR, V18, P271
[4]   Norepinephrine and acetylcholine mediation of the components of reflexive attention: implications for attention deficit disorders [J].
Beane, M ;
Marrocco, RT .
PROGRESS IN NEUROBIOLOGY, 2004, 74 (03) :167-181
[5]   Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder [J].
Biederman, J ;
Spencer, T .
BIOLOGICAL PSYCHIATRY, 1999, 46 (09) :1234-1242
[6]   Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder [J].
Biederman, J ;
Heiligenstein, JH ;
Faries, DE ;
Galil, N ;
Dittmann, R ;
Emslie, GJ ;
Kratochvil, CJ ;
Laws, HF ;
Schuh, KJ .
PEDIATRICS, 2002, 110 (06) :e75
[7]   Chamber-specific alterations of norepinephrine uptake sites in cardiac hypertrophy [J].
Böhm, M ;
Castellano, M ;
Flesch, M ;
Maack, C ;
Moll, M ;
Paul, M ;
Schiffer, F ;
Zolk, O .
HYPERTENSION, 1998, 32 (05) :831-837
[8]  
BRUSS M, 1993, HUM GENET, V91, P278
[9]   Noradrenaline transporter expression in the pons and medulla oblongata of the rat: localisation to noradrenergic and some C1 adrenergic neurones [J].
Comer, AM ;
Qi, JG ;
Christie, DL ;
Gibbons, HM ;
Lipski, J .
MOLECULAR BRAIN RESEARCH, 1998, 62 (01) :65-76
[10]  
CUBELLS JF, 1995, J NEUROCHEM, V65, P502